Long COVID (post-acute sequelae of SARS-CoV-2 infection, or PASC) affects an estimated 7-15% of people who’ve had COVID-19, with persistent fatigue, brain fog, dysautonomia, post-exertional malaise, and other symptoms. Research has expanded substantially since 2020, with the NIH RECOVER initiative coordinating major US research efforts. Multiple mechanisms are being studied, though no specifically approved long COVID treatments exist. For patients with long COVID, clinical trials for long covid represent meaningful options. This guide covers how to find long COVID trials, active research areas, and resources.
Categories of long COVID trials
Active long COVID trials in 2026 include:
Antiviral approaches: Paxlovid trials for long COVID (RECOVER-VITAL completed; new approaches), other antivirals.
Anti-inflammatory and immunomodulators: Targeting persistent inflammation potentially driving symptoms.
Cardiac and dysautonomia treatments: POTS, exercise intolerance, and cardiovascular symptoms.
Cognitive symptoms: Brain fog, memory issues, and cognitive dysfunction.
Microclot research: Approaches addressing potential microcirculatory issues.
Multimodal rehabilitation: Structured programs combining graded exercise, cognitive rehabilitation, and other approaches (with care given the post-exertional malaise risk).
Where to find long COVID trials
Resources:
- ClinicalTrials.gov
- NIH RECOVER initiative — major federal coordinating effort
- Long COVID Alliance
- Major academic medical centers with long COVID clinics
The RECOVER initiative is the primary US federal effort coordinating long COVID research. Multiple sub-studies are testing different interventions.
Typical eligibility
Common inclusion criteria:
- Documented prior SARS-CoV-2 infection
- Persistent symptoms beyond 3 months
- Specific symptom profile depending on trial
Common exclusion criteria:
- Other diagnoses that could explain symptoms
- Significant pre-existing conditions that could confound
- Pregnancy
Frequently Asked Questions
What is the RECOVER initiative?
NIH-funded research consortium studying long COVID, including observational studies and intervention trials. Major source of long COVID research activity.
Are Paxlovid trials for long COVID still active?
Initial trials had mixed results. Newer trials with refined patient selection continue.
What about microclot-targeted approaches?
Active area but with mixed evidence. Be cautious of unregulated treatments outside formal trials.
Are pediatric long COVID trials available?
Yes, with specific pediatric long COVID research efforts.
How long do long COVID trials typically last?
Most trials are 3-12 months with various endpoints.
The bottom line on long COVID trials
Long COVID research is rapidly expanding with the RECOVER initiative and other major efforts. Multiple mechanisms in active investigation. For patients with persistent symptoms, trials offer access to investigational approaches and intensive monitoring.